Amissa

Market position

Amissa operates in a menopause and perimenopause care market that is drawing increasing attention and new entrants; adjacent companies named alongside it include the virtual menopause providers Midi Health, Evernow and Gennev. Amissa differs from these in selling clinician-facing data infrastructure rather than direct care, and describes its position relative to wearable makers such as Oura and Whoop as complementary rather than competing.

Company leadership positions Amissa as the only platform focused on the connectivity layer between patient data and clinicians in menopause care, as opposed to virtual care providers, wearables, supplements or medication. Rather than expecting clinicians to interpret wearable PDFs during a 15-minute appointment, the product standardizes fragmented inputs into a short pre-visit summary, and adds symptom fields that the company says are absent from standard EHRs.

Technology

The platform integrates with consumer wearables (Apple Watch, Oura, Garmin, Whoop), structured questionnaires such as the Menopause Rating Scale, patient-entered symptom logs and EHR data, and applies AI to consolidate them into a concise clinical summary delivered inside the provider's EHR. Earlier descriptions characterize the system as cloud-scale data analytics for remote patient monitoring via smartwatches.

Go-to-market

Amissa validated its concept through customer discovery interviews with more than 500 clinicians, researchers, health system leaders and patients, and is piloting the application with local clinicians in Charlotte to refine the user experience before broader expansion. Participation in the Techstars AI Health program in Baltimore provided access to organizations including MedStar, Johns Hopkins and Blue Cross Blue Shield.

Clinical practices and the clinicians within them — particularly OB-GYNs and primary care physicians treating women in perimenopause and menopause — and, indirectly, the patients who track symptoms on the platform. The company notes research finding that 93% of OB-GYN and primary care residents do not feel comfortable managing menopausal symptoms.

Geography

Headquartered in Charlotte, North Carolina, with pilot deployments among local Charlotte clinicians and clinical practices across the United States; the company participated in an accelerator program based in Baltimore.

History

The company was founded in 2017 and initially operated as Amissa Health, a bootstrapped AI platform using smartwatches to remotely monitor patient mental and physical health in the context of rare diseases and dementia, including Alzheimer's and Parkinson's; it was led at that time by Jon Corkey, a retired Navy Special Operations Officer whose military career ended with a rare disease diagnosis. In October 2023 the company won the Charlotte Veteran Startup Showcase and a $50,000 grant. Early development was supported by a National Institutes of Health Small Business Innovation Research grant, which funded an extended customer discovery phase. The company publicly launched its AI menopause care platform in January 2026, participated in the Techstars AI Health program in Baltimore, and as of July 2026 was working to close a pre-seed round.

Risks & controversies

The company was still finalizing its pre-seed round as of July 2026 with a team of three, and its clinical footprint remains small at approximately 10 practices. Management notes that the menopause and perimenopause category is attracting a growing number of competitors.